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INTRODUCTION 
Ultrasound evaluation of the heart, or echocardiography, is now the most widely used 
cardiac imaging procedure. It is well established as a reliable method for evaluating cardiac 
function and anatomy. Ultrasound image quality, however, is limited by the small differences 
in density between organ structures in the body. Most tissue interfaces in vivo transmit or 
scatter ultrasound energy; little energy is reflected back to the transducer causing poor 
resolution. This situation can be improved by the use of an ultrasound contrast agent, which 
introduces a highly echo reflective interface in vivo. 
Gramiak et al [1] first described the use of free gas bubbles contained in various 
agitated solutions, such as dextrose or saline, as ultrasound contrast agents. Gas bubbles 
suspended in a liquid provide one of the best echo genic interfaces because ofthe vastly 
different densities ofliquid and gas. But such suspended bubbles are relatively large, with an 
UnknOVv11 or irreproducible size distribution and concentration. Freely suspended bubbles are 
also inherently short lived due to spontaneous coalescence, leading to concerns of safety and 
poor contrast effects. Attempts were made by Ziskin et al [2] to create more stable and 
reproducible bubble suspensions using materials such as agitated Renografin (high viscosity), 
carbonated water, and ether. Tickner et al [3] employed microbubbles trapped in gelatin with 
limited success. Some investigators sacrificed echoreflectivity for improved longevity by 
using solid material more dense than tissue, such as suspensions of collagen [4] and gelatin 
[5], to generate ultrasonic echoes. These early approaches suffered from an inability to 
generate a stable, echoreflective agent that would survive introduction into the bloodstream 
long enough to accumulate reproducible images. 
Sonication of solutions such as sorbitol or dextrose was shown to produce microbubble 
contrast agents with somewhat improved persistence and with a smaller size range capable of 
passing through capillary beds [6,7]. Feinstein [8] continued to advance the sonication 
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approach by the treatment of heat-sensitive proteins such as human albumin. Sonication of 
albumin produced high concentrations of micro bubbles encapsulated in a shell ofthennally 
denatured albumin protein. These micro spheres were oflimited stability, but formed the 
foundation of albumin microsphere technology. 
Ideally, a commercially viable ultrasound contrast agent must have reasonable shelf-
life and demonstrated high safety profile. The agent must have a defined, consistent 
concentration and a size range small enough to survive lung filtration « lO microns), while 
maintaining sufficient acoustic efficacy to illuminate the chambers and muscle of the heart and 
perfuse the distal organs such as the liver and kidneys. 
Albumin microsphere technology has been commercialized and offers a safe and 
highly effective modality for enhancing ultrasound imaging through the use of contrast. The 
echo reflectivity of albumin microspheres are virtually identical to that of free, uncoated gas 
bubbles of the same diameter and are small enough to flow freely through capillaries. A single 
dose of agent delivers only 0.1 milliliter of gas without any danger of size increase due to 
coalescence, aggregation or expansion. A suspension of albumin microspheres is exceedingly 
stable. A vial of product can be stored, transported and agitated repeatedly without loss of 
microspheres or a change in size. The thin shell of insoluble human albumin is responsible for 
stability, efficacy and the high safety profile of albumin microspheres. This shell protects and 
maintains an individual spherical gas core, both in vitro and in vivo and is essentially 
biologically invisible in the bloodstream. Dosages of albumin microspheres up to 400-fold 
over efficacy have been used without any physiological effect in animal models. 
FIRST GENERATION CONTRAST AGENTS - ALBUNEX® 
First generation ultrasound agents utilized microbubbles of air or atmospheric gases in 
several formats: 1) dissolvable matrices, such as sugars (Echovist) [9]; 
2) emulsified into aqueous suspensions with lipid agents (Aerosomes) [lO]; 3) encapsulated in 
polymers (Microballons) [11]; and 4) encapsulated in insoluble protein shells (ALBUNEX) 
[12). The first ultrasound contrast agent to be approved for medical use in the United States 
was ALBUNEX, a stable and well defined suspension of echo genic albumin microspheres. A 
10 mL dose of ALBUNEX via peripheral vein of the arm enhances the contrast of ventricular 
chambers of the heart and improves of endocardial border definition. ALBUNEX has been 
shown to be safe in over 20,000 patient administrations. 
Air containing agents such as ALBUNEX, however, have difficulty maintaining a 
strong contrast effect after passage through the lungs and the left side of the heart. The 
persistence of ALBUNEX in the blood is iess than one minute. Contrast intensity diminishes 
through the circulation and perfusion of the agent into the blood flow of the heart muscle and 
distal organs is weak or nonexistent. The limited in vivo robustness of air-containing 
ultrasound contrast agents is due to the solubility of atmospheric gases in the bloodstream. 
Although ALBUNEX, and other agents of this generation, provide a mechanism for 
maintaining a stable popUlation of micro bubbles in aqueous suspension, the coatings are 
permeable to dissolved atmospheric gases. The blood is undersaturated in dissolved air, 
particularly oxygen, and the air component of ALBUNEX begins to dissolve into the 
circulation immediately after injection. As a result, a sufficient amount of encapsulated air in 
the micro spheres may not reach the left cardiac chambers to generate echoes. Increasing the 
amount of air by increasing the dose of ALBUNEX improves the circulation lifetime, but this 
agent is generally incapable of persisting throughout the circulation and perfusing myocardium 
and other tissues. 
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SECOND GENERATION CONTRAST AGENTS - OPTISONTM 
The limited circulation lifetime of the first generation contrast agents was addressed 
either by incorporating the echoreflective air component into less penneable coatings, such as 
organic polymers and cross-linked proteins, or by employing less soluble gaseous compounds. 
The second approach proved to be more effective. Gases such as sulfur hexafluoride and 
perfluorocarbon, or the vapors of low boiling point liquids, such as perfluoropentane and 
perfluorohexane are relatively insoluble in aqueous media. The contrast effect of agents 
prepared with these compounds is greatly extended due to the slower dissolution ofthe gas 
component into the surrounding fluids. The next, or "Second Generation," contrast agents in 
development all contain insoluble gases or vapors as a component. These agents persist in the 
circulation and survive passage beyond the lungs and the left heart. Contrast can now be 
observed in the left side of the heart, the capillary flow through the myocardium and even 
perfusion through the distal organs such as the kidney and liver. 
The next generation of commercial contrast agents have taken the fonn of: 
1) liquid/liquid emulsions (Echogen) [13,14]; 2) gas containing liposomes (DMP 115) [15] 
and polymers (SonoVue) [16]; 3) liquid adsorbed onto dispersed solids (Imagent) [I7] and; 
4) gas filled albumin microspheres (OPTISON) [18]. OPTISON is closely related to 
ALBUNEX and was developed to extend in vivo perfonnance, while maintaining safety and 
effectiveness. The fonnulation of ALBUNEX was altered to extend in vivo lifetime by 
incorporating perfluoropropane (C3Fg) into the microsphere core. OPTISON is also an 
intravenous contrast agent that improves the delineation of cardiac borders and ventricular 
chambers. In addition, OPTISON is capable of persisting throughout the circulation, and is 
ultrasonically observable in the myocardium and distal organs as a perfi.Ision agent. 
PROPERTIES OF ALBUMIN MICROSPHERES 
Fonnation 
OPTISON is produced by the ultrasonic treatment of albumin solution in the presence 
of perfluoropropane. Albumin is the major protein component of serum and is widely used to 
replenish lost blood volume. The OPTISON process uses Albumin Human 5%, USP diluted 
with 0.9% Sodium Chloride Injection, USP to a concentration of approximately 1%. 
Perfluoropropane is a relatively insoluble, chemically inert and nontoxic gas having a boiling 
point of -29.5°C. It is approved in the United States as a medical device for ophthalmic-
related procedures. A stream of 1% albumin is wanned to a temperature just below the 
thennal denaturation point of the protein and combined with a stream of perfluoropropane gas. 
The mixture is treated with high intensity ultrasound at a frequency of 20 kHz, far above the 
energy level employed for medical ultrasound. The ultrasound pressure waves in the 
liquid/gas mixture causes suspended gas microbubbles to rapidly expand and contract 
generating a minute amount of heat. The heat radiates outward from the microbubble and is 
sufficient to convert a small amount ofthe soluble protein medium (5-7% total) to a spherical, 
non-rigid denatured protein shell. The protein shell encapSUlates a continuous 
perfluoropropane gas core less than 1 picoliter (10-12 L) in volume. The shell is about 15 run 
thick, or several albumin molecules deep. The unconverted soluble albumin protein is 
unaltered and remains in solution as the suspending liquid medium. The process is sterile and 
the product is filled into single use glass vials and sealed under an atmosphere of the process 
gas. The manufacture of ALBUNEX is identical, but utilizes mr as the process gas and a more 
concentrated albumin solution (5%). 
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Specifications 
The albumin micro spheres are buoyant and float to the surface of an undisturbed vial 
over several minutes. The microspheres disperse readily by gentle agitation or rotation to a 
homogeneous milky suspension ready for injection. The microsphere fraction of OPTISON 
ranges in size from about I to 20 microns diameter, with 92.5 % below 10 microns. The 
specifications for concentration (5.0 - 8.0 x 108 microspheres/roL) and size distribution (2.0-
4.5 micron mean diameter) are very similar to those for ALBUNEX (3.0 - 5.0 x 108 
microspheres /mL and 3.0 - 5.0 microns, respectively). Since microspheres in both OPTISON 
and ALBUNEX are similar in size to red blood cells, they are capable of passing through the 
capillary bed of the lungs to the heart and other organ systems of interest for visualization. A 
photomicrograph of OPTISON microspheres is shown in Fig. 1. 
Stability 
Unlike ALBUNEX and OPTISON, unencapsulated gas microbubbles dispersed in a 
liquid medium are unstable and tend to coalesce. The energy involved in maintaining the 
radius of curvature of two small bubbles of gas suspended in a liquid is greater than 
maintaining one larger bubble. The energy released upon coalescence is sufficient to disrupt 
the liquid/gas interface ofthe smaller bubbles, resulting in their spontaneous association into a 
larger structure. In contrast, the micro spheres of both ALBUNEX and OPTISON are stable 
and the encapsulated gas microspheres do not coalesce. The solid shell material is insoluble 
and maintains the microsphere gas core in a stable volume by preventing direct contact of 
gas/liquid interface. The energy required to disrupt the solid shell of protein microspheres 
cannot be found in the potential energy released in forming a larger bubble. Microscopic 
Figure 1. Photomicrograph (400X) of OPTISON 
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observation of microspheres under conditions mimicking packaged and in vivo conditions 
failed to record spontaneous coalescence between two microspheres, or aggregation into muIti-
sphered structures. Any interaction in suspension is random and transient. Stability evaluation 
of product under storage conditions confirms the maintenance of microsphere concentration 
and size distribution, strongly supporting the lack of microsphere interaction. 
Albumin microspheres diluted into fresh whole blood are likewise non-interactive, and 
absent of any effect on red blood cells or other serum components. Exposure of albumin 
microspheres to medical ultrasound (2-5 mHz) also fails to produce coalescence or 
aggregation. Ultrasound induced associations have been observed in flowing suspensions at 
higher than physiological concentration due to converging pressure waves. Such associations 
are transient and fully reversible after the microspheres exit the area of ultrasonic irradiation 
[20]. 
Figure 2 shows the collapse ofthe albumin shell as the gas core is slowly removed, 
leaving random shaped debris of denatured protein. This material can be collected by 
centrifugation or filtration and redissolved by treatment with detergents or chaotropic agents. 
Resolubilization of the shell material, followed by dialysis, retums the protein to native 
conformation, demonstrating the encapSUlation process does not chemically alter the albumin 
protein. 
Efficacy 
The shell of albumin microspheres is permeable to gas molecules in the dissolved 
state. ALBUNEX microspheres diluted into an aqueous medium that is undersaturated in 
dissolved air will readily solubilize the core, depleting the microspheres of air until the 
solution is saturated in dissolved air. OPTISON has an insoluble albumin shell identical to 
Figure 2. Photomicrograph (400X) of OPTISON with partial depletion of the gas core. 
Microspheres were incubated for several minutes in a flowing stream of degassed buffer. 
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ALBUNEX, but the core gas is perfluoropropane, which is 32-fold less soluble than air 
(0.00072 mL/mL at 15°C). Blood is always undersaturated with respect to dissolved 
atmospheric gases and perfluoropropane. Introduction of ALBUNEX or OPTISON into the 
blood stream results in a continuous depletion ofthe gas core and collapse of the shell 
structure, resulting in the loss of echogenicity. OPTISON persists longer in the circulation 
because the loss of perfluoropropane gas from the core is slower. Perfluoropropane does not 
possess any inherent properties for superior echogenicity. Superior contrast and perfusion 
effect is due to greater persistence in the circulation. Greater in vivo persistence, up to several 
minutes, allows OPTISON to penetrate the capillary circulation and effectively image 
myocardial perfusion, as well as blood flow through the kidney, liver and other distal organs. 
Albumin microspheres are stable and echogenic at the time of manufacture and, unlike 
most other agents under development, do not require a preactivation step. The product is fully 
qualified at the time of manufacture. Other agents under development require the clinician to 
generate the echogenic entity just prior to injection. Perfluoropentane emulsion, for example, 
is treated by hypobaric activation [19] in a specialized syringe to vaporize a small amount of 
the liquid perfluoropentane component (b.p. 29.5°C). The product must then be injected 
immediately. Other products under development require vigorous mechanical agitation to 
induce the formation of insoluble gas or vapor microbubbles. 
Thermal Expansion 
Unlike contrast agents composed ofliquids that vaporize in the blood stream, albumin 
microspheres exposed to a temperature gradient from 18°C to 38°C over five minutes fail to 
reveal any clear increase in size, or alteration in morphology. This is consistent with the 
physical chemistry of gases. The relationship of gas volume to temperature follows the laws 
of Charles and Gay-Lussac, which state that for every 1°C rise in temperature, any gas 
expands by 11273 of its volume at DOC at constant pressure. The injection ofOPTISON at 
ambient temperature (20°C) into the blood stream results in an increase in temperature of 
17°C. According to the gas law, this would result in an increase in volume of approximately 
17/273, or 6%, if the gas were free to expand. Since the volume ofa sphere is proportional to 
the cube of the radius, this would represent a maximum possible increase in diameter of only 
2%. Additionally, injection in vivo imposes a pressure increase of approximately 100 mm Hg. 
This is an increase in pressure of approximately 13% above ambient. According to Boyle's 
Law, this would result in an 11.5% reduction in gas volume, or a 4% decrease in diameter. 
Therefore, the potential enlargement of albumin microspheres due to thermal expansion ofthe 
gas core is more than offset by the compression exerted by in vivo blood pressure. 
Safety - In Vivo Properties 
One dose (3 mL) ofOPTISON contains approximately 30 milligrams of soluble native 
albumin, 1.5 milligrams insoluble albumin, and less than one milligram (125 ~L at STP) 
perfluoropropane gas. Upon injection, the gas core of the microspheres begins to slowly 
dissolve. The bloodstream cannot become saturated with dissolved perfluoropropane due to 
insufficient mass. Solubilized perfluoropropane gas exits, quantitatively, through the lungs 
within several minutes after injection, without chemical alteration. Experimental animals 
breathing 50% perfluoropropane over several hours were reported unaffected, without any 
direct or potentiating anesthetic effect [21]. 
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Adverse events reported for OPTISON during clinical trials were minor and similar in 
nature and number to that reported for ALBUNEX. Doses of 400-fold ofOPTISON in 
animals (equivalent to 1.2 L in an adult individual) and up to 90-fold in cardiac patients have 
been given without incident. Alteration or changes in heart rate, blood pressure, or 
oxygenation have not been observed. Albumin microspheres, being composed of human 
protein, are immunologically inert in human patients. The insoluble shell material is 
metabolized in the liver. 
Human albumin in 5% solution is in routine use throughout the world. It is purified 
from human serum by cold ethanol precipitation (Cohn V fractionation). It is injected 
intravenously, typically in units of250 mL. Properly manufactured, albumin has been used 
for almost 50 years without reported incidence of transmission of HI V, Hepatitis B, Hepatitis 
C, and Creutzfeldt-Jakob disease (CJD) [22]. 
CONCLUSION 
OPTISON, like ALBUNEX, is intended as an intravenous contrast agent to improve 
the delineation of cardiac borders and ventricular chambers. OPTISON is more effective than 
ALBUNEX in clinical practice at reduced doses because of the prolonged ultrasound contrast 
effect which also imparts the property oftissue perfusion. Albumin microsphere technology 
delivers safe, well defined, and highly efficacious contrast capability to medical ultrasound 
imaging at very low doses. 
The advantages of albumin microsphere technology include: 
I. Ease of Use - ALBUNEX and OPTISON are readily resuspended by gentle hand agitation. 
The products are injected directly without preactivation or the use of specialized equipment. 
Albumin microspheres are fully qualified at the time of manufacture. 
2. Small Dose Requirements - A dose of3 mL delivers over a billion micro spheres 
containing approximately 0.1 mL total gas. 
3. Highly Efficacious - The insoluble rnicrosphere shell does not dampen echogenicity. 
Small size distribution is optimal for ultrasound reflection and vascular penetration. In vivo 
persistence allows imaging for several minutes. 
4. Stable - The product has an approved shelf life of 1 year, with no evidence of coalescence 
or aggregation. 
5. Biologically Inert - The protein components (soluble aqueous vehicle & insoluble shell) are 
composed of human albumin and are free of immunological effects. The perfluoropropane 
core is exhaled quantitatively without biochemical modification. 
6. High Safety Profile - Microspheres are resistant to coalescence, aggregation and expansion 
in the circulation. ALBUNEX has been used without serious adverse events on over 20,000 
patients. OPTISON has been injected into animals and human patients at 400X and 90X the 
efficacious dose, respectively, without physiological effect. 
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